76 Business View - February 2016
as providing development and production services for
drugs in finished dosage forms. Siegfried works with
many partner companies that assist with its manu-
facturing processes. One such partner is Proconex, a
leading provider of automation, integration, and instru-
ment services in the Mid-Atlantic region. Some of Sieg-
fried’s customers are exclusive, with the company ful-
filling all of their chemical synthesis, formulation, and
drug product needs. “Whatever they want us to do,”
says Späne. “On the other hand, we have an opiate
portfolio. We have ownership of 80 products and we
sell these APIs to a very broad customer base: phar-
maceutical and innovative engineering companies.”
In a very competitive sector, Späne believes that Sieg-
fried has significant advantages, not the least of which
is the company’s inherited knowhow. “That’s the big
benefit of Siegfried,” she states. “If you want to be a
service provider you are in a better position if you have
a broader portfolio. We didn’t need to build up or to ac-
quire a culture of how to do formulations or drug prod-
uct manufacturing; we had the inherited knowledge.
And now, when we acquire companies, we already
have the two divisions as one in our company. There-
fore it is much easier to integrate all our acquisitions
A Global Network
of Competencies
Zofingen
Switzerland
Drug Substance / Drug Product
Hameln
Germany
Drug Product
Saint-Vulbas
France
Drug Substance
Evionnaz
Switzerland
Drug Substance
Pennsville
USA
Drug Substance
Irvine
USA
Drug Product
Hal Far
Malta
Drug Product
Minden
Germany
Drug Substance
Nantong
China
Drug Substance
MANUFACTURING
